US Patent

US11135155 — Liquid naloxone spray

Formulation · Assigned to Hikma Pharmaceuticals USA Inc · Expires 2034-08-26 · 8y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects stable liquid formulations of naloxone for intranasal administration to treat opioid overdose, dependence, and congenital insensitivity to pain with anhidrosis.

USPTO Abstract

The invention provides stable liquid formulations containing naloxone, a pharmaceutically acceptable salt or a derivative thereof. The invention further provides methods for treating opioid overdose, opioid dependence, and congenital insensitivity to pain with anhidrosis by administering the liquid formulations of the present invention intranasally to a patient in need thereof. Further, the invention provides a method of treating opioid dependence, opioid overdose, and congenital insensitivity to pain with anhidrosis by administering intranasally the naloxone formulations of the present invention.

Drugs covered by this patent

Patent Metadata

Patent number
US11135155
Jurisdiction
US
Classification
Formulation
Expires
2034-08-26
Drug substance claim
No
Drug product claim
Yes
Assignee
Hikma Pharmaceuticals USA Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.